Skip to main contentSkip to navigationSkip to search

NorthX Biologics Welcomes Dr Janet Hoogstraate as New CEO Following Merger with Valneva Clinical Trials Manufacturing Unit

We are announcing the appointment of a new CEO Dr. Janet Hoogstraate. Janet is a distinguished leader within the biopharmaceutical sector and this move follows the company's strategic merger with Valneva Sweden’s Clinical Trial Manufacturing Unit.

Janet will succeed Helena Strigård who in a short time navigated NorthX through several important milestones, including global promotion of NorthX’ services and the recent merger.

Press release here: